TY - JOUR
T1 - Clinical islet transplantation experience of the University of California Islet Transplant Consortium
AU - Brunicardi, F. Charles
AU - Atiya, Azmi
AU - Stock, Peter
AU - Kenmochi, Takashi
AU - Une, Satoshi
AU - Benhamou, Pierre Y.
AU - Watt, Philip C.
AU - Miyamato, Masaaki
AU - Wantanabe, Yoshi
AU - Nomura, Yasu
AU - Kleinman, Robert
AU - Arita, Seiji
AU - Ohtsuka, Satoki
AU - Shevlin, Linda
AU - Rosenthal, Thomas
AU - Busuttil, Ronald W.
AU - Mullen, Yoko
AU - Passaro, Edward
N1 - Funding Information:
ISLET TRANSPLANTATIONh as generally been considered to be of limited medical success in that only 3.0% of 214 adult islet allograft recipients have achieved insulin independence at 1 year or later. However, when the Islet Transplant Registry data are examined further, 27% have achieved insulin independence and 45% of the Supported by National Institutes of Health grant IR29DK 464414)1, Jerry's Foundation for Diabetes Research, Nora Eccles Treadwell Foundation, Oberkotter Family Foundation, and the Barbara Davis Family. Presented at the Sixteenth Annual Meeting of the AmericanA ssocia-tion of Endocrine Surgeons, Philadelphia, Pa., April 23-25, 1995. Reprint requests: F. Charles Bruuicardi, MD, FACS, BaylorC ollege of Medicine, Divisiono f General Surgery, 1 Baylor Plaza, Houston, TX 77O30. 11/6/66965 patients have functioning islet grafts at 1 year if state-of-the-art criteria are used. l' 2 These criteria include (1) transplantation of at least 8000 islet equivalents per kilogram body weight (IEQs/kg bw), (2) use of the portal vein as the implantation site, (3) induction immunosuppression, and (4) postoperative management with strict blood glucose control by using intravenous insulin. ~ In consideration of the Diabetes Control and Complications Trial, which recently showed that improvements in glucose control prevent long-term complications of diabetes, state-of-the-art islet transplantation could represent an efficacious treatment for a subpopulation of patients with diabetes. However, the potential of islet transplantation in its current state remains undetermined. ~' 4 The University of California Transplant Centers from Los Angeles, Torrance, San Francisco, Sacramento, Ir-
PY - 1995/12
Y1 - 1995/12
N2 - Background. The University of California Islet Transplant Consortium was formed to evaluate the feasibility of performing clinical islet transplantation at different transplant centers by using a single centralized islet isolation laboratory. Methods. From July 1992 through February 1995 seven adult islet transplantations were performed, six allografts and one autograft. Once procured, human pancreata were brought to the UCLA-VA Islet Core Laboratory for islet isolation and purification, which were then transported to different centers for transplantation. Patients 1 through 3 received their transplants in Los Angeles, patient 4 received her islet transplant in Torrance, and patients 5 through 7 received their transplants in San Francisco. Results. Although none of these patients achieved insulin independence, four of seven had functioning grafts longer than 6 months as indicated by circulating C-peptide level greater than 0.7 ng/ml. Furthermore, improved glucose control as shown by a decreased insulin requirement was seen in 57% (four of seven patients) of these patients. The ability to isolate islets at a single laboratory and transport them long distances to different centers was shown in patients 4 through 7. Conclusions. Islet transplantation can be performed with improvements in blood glucose control, and islets can be isolated at a centralized location and successfully transported to different centers for transplantation.
AB - Background. The University of California Islet Transplant Consortium was formed to evaluate the feasibility of performing clinical islet transplantation at different transplant centers by using a single centralized islet isolation laboratory. Methods. From July 1992 through February 1995 seven adult islet transplantations were performed, six allografts and one autograft. Once procured, human pancreata were brought to the UCLA-VA Islet Core Laboratory for islet isolation and purification, which were then transported to different centers for transplantation. Patients 1 through 3 received their transplants in Los Angeles, patient 4 received her islet transplant in Torrance, and patients 5 through 7 received their transplants in San Francisco. Results. Although none of these patients achieved insulin independence, four of seven had functioning grafts longer than 6 months as indicated by circulating C-peptide level greater than 0.7 ng/ml. Furthermore, improved glucose control as shown by a decreased insulin requirement was seen in 57% (four of seven patients) of these patients. The ability to isolate islets at a single laboratory and transport them long distances to different centers was shown in patients 4 through 7. Conclusions. Islet transplantation can be performed with improvements in blood glucose control, and islets can be isolated at a centralized location and successfully transported to different centers for transplantation.
UR - http://www.scopus.com/inward/record.url?scp=0028850671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028850671&partnerID=8YFLogxK
U2 - 10.1016/S0039-6060(05)80101-1
DO - 10.1016/S0039-6060(05)80101-1
M3 - Article
C2 - 7491541
AN - SCOPUS:0028850671
SN - 0039-6060
VL - 118
SP - 967
EP - 972
JO - Surgery
JF - Surgery
IS - 6
ER -